Physician profile

Michael A Rivera

Obstetrics & Gynecology · Anderson, SC

NPI 1235173048

$977.26

in general payments reported to CMS, 2019-2025

26 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $283.38 2019-2021
Pfizer INC. $93.99 2020-2021
Novartis Pharmaceuticals Corporation $68.30 2019-2021
Astrazeneca Pharmaceuticals LP $48.95 2019-2020
Eisai INC. $48.65 2019-2021
Ipsen Biopharmaceuticals, INC $46.55 2019
Merck Sharp & Dohme LLC $40.78 2021
Amgen INC. $33.67 2019-2021
Daiichi Sankyo INC. $31.24 2019
Coherus Oncology, INC. $28.07 2020-2021
Takeda Pharmaceuticals U.S.A., INC. $26.17 2019-2020
Deciphera Pharmaceuticals INC. $23.90 2021
Seagen INC. $19.05 2021
Acrotech Biopharma INC. $18.60 2021
Regeneron Healthcare Solutions, INC. $18.03 2021
Show all 26 companies
CompanyGeneral paymentsYearsTop products
Myovant Sciences INC. $16.06 2021
Lilly USA, LLC $15.91 2021
Alexion Pharmaceuticals, INC. $14.67 2021
Bayer Healthcare Pharmaceuticals INC. $13.93 2019
Secura Bio, INC. $13.30 2020
Roche Diagnostics Corporation $13.28 2019
Janssen Biotech, INC. $12.73 2019
Celgene Corporation $12.72 2019
Allergan, INC. $12.41 2020
Incyte Corporation $11.65 2021
Amag Pharmaceuticals, INC. $11.27 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael A Rivera

$977.26

in general payments reported 2019-2025

Years
2019-2021
Top company
Abbvie INC.

https://glasscript.com/doctor/1195335/michael-a-rivera

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.